Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 4/20 | 0.41 |
| ▸ | BRD2 | P25440 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14080073 | 0.90 | PARP14 (0.44) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL14072010 | 0.87 | KDM4E (0.64) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL14080067 | 0.81 | ALDH1A1 (0.46) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8199240 | 0.81 | BRD4 (0.61) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL14072071 | 0.79 | GABRP (0.44) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL14072078 | 0.79 | GABRP (0.49) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL4383240 | 0.75 | ALDH1A1 (0.69) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8190292 | 0.75 | ALDH1A1 (0.65) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| SCHEMBL8202194 | 0.74 | HSD17B10 (0.51) | KDM4EALDH1A1HPGDHSD17B10GAA | |
| Water SCHEMBL11479741 | 0.74 | ALDH1A1 (0.67) | KDM4EALDH1A1HPGDHSD17B10GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008109178-A1 | METALLOPROTEASE INHIBITORS CONTAINING A SQUARAMIDE MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221128-A1 | Metalloprotease inhibitors containing a squaramide moiety | MMP11, MMP13, MMP14 | KDM4E 685/4885ALDH1A1 2056/4885HPGD 199/4885 |
| US-20080221095-A1 | Metalloprotease inhibitors containing a heterocyclic moiety | MMP13, MMP11, MMP3 | KDM4E 572/4885ALDH1A1 1569/4885HPGD 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.